Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent.
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 19 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 19 Dec 2011 Actual patient number is 121 according to ClinicalTrials.gov.
- 19 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.